China Grand Pharmaceutical and Healthcare
China Grand Enterprises Ranks 15 at Top 100 Accolade in China’s Pharmaceutical Industry
China Grand Enterprises Ranks 15 at Top 100 Accolade in China’s Pharmaceutical Industry The 32nd China Pharmaceutical Industry Information Annual Conference 2015 was recently held in Chengdu by China National Pharmaceutical Industry Information Center. During the Conference, “Top Accolade in China’s Pharmaceutical Industry in 2014” was officially announced. China Grand Enterprises, Inc. (China Grand Enterprises) ranks at 15 (exclude Hangzhou East China Pharmaceutical Group Co., Ltd). According to the statistics and analysis from China National Pharmaceutical Industry Information Center, comparing to the standard calculation, the revenue of the Top 100 pharmaceutical enterprises in 2014 increased in 16.5%, 3.4% higher comparing with the industry average, total profits has an increment of 14.4%. The Top 100 Accolade in China’s Pharmaceutical Industry is the only official data that reflects the economic situation in China’s pharmaceutical industry, by ranking the top 100 pharmaceutical companies based on their revenue generated from pharmaceutical businesses. China Grand Enterprises attaches great importance to the pharmaceutical and healthcare business, actively support the development of its pharmaceutical sector, since 2014, paying more attention to the development opportunities of international pharmaceutical market. China Grand Pharmaceutical and Healthcare Holdings Limited (China Grand Pharm, stockcode: 00512) is the only international capital market platform to China Grand Enterprises, started to research and follow international pharmaceutical market development opportunities in 2014, and in May 2015, the pursuant to the acquisition of Cardionovum GmbH with CDB Equipment Manufacturing Investment Fund Co. Ltd, the Company engages in the development, manufacturing and distribution of advanced interventional cardiovascular medical devices such as coronary drug eluting stent (DES) and drug-eluting balloons (DEB), taking this opportunity, China Grand Pharmaceutical and Healthcare Holdings Limited, soon will take action on internationalization strategy and international markets, with more successful records, to provide fruitful return to the shareholders. China Grand Enterprises Inc. End of Press Release +++++ Document: http://n.equitystory.com/c/fncls.ssp?u=SUVOGUKGVY Document title: China Grand Enterprises Ranks 15 at Top 100 Accolade in China’s Pharmaceutical Industry Key word(s): Miscellaneous 15/07/2015 UTC+8 Dissemination of a Press Release, transmitted by EQS TodayIR – a company of EQS Group AG. The issuer is solely responsible for the content of this announcement. Media archive at www.todayir.com |
378149 15/07/2015 UTC+8 |